NCT04555785View on ClinicalTrials.gov

Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2028

Conditions
Bleeding
Interventions
DRUG

Wilate

Wilate ® will be given with platelets in cases of severe bleeding. Wilate ® is a 1:1 balanced mixture of von Willebrand Factor (2'000 IU) and Coagulation factor VIII (2'000 IU) and as such has anti-haemorrhagic potential. It is extracted from plasma, freeze-dried and virus-inactivated.

OTHER

Placebo

Empty placebo will be given with platelets in cases of severe bleeding.

Trial Locations (1)

4031

RECRUITING

University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER